@RaceOncology, a few questions:
1) Will early trial participants be able to move up onto higher Bisantrene doses for future combination cycles as each dose level is cleared (assuming they stay on the trial long enough of course), or will they be fixed at whatever their initial dose level was when they were enrolled in the trial?
2) Whilst we will have to wait for concrete data on cardio-protection and anti-cancer efficacy, can we expect anything interesting to be released earlier from the micro-level data that is being collected and (hopefully) will correspond to those broader goals being achieved - e.g. FTO inhibition/m6A levels, ctDNA levels, cardiac health markers, etc.?
3) Do we expect there will be a trade-off point between anti-cancer efficacy and cardio-protection efficacy at some point? i.e. a dose level where increasing the dose of Bisantrene may improve anti-cancer effectiveness, but due to the combined Dox/Bisantrene toxicity, it is resulting in reduced cardio-protection? Or are the likely dosing levels going to be hitting other limitations prior to cardio-protection being compromised?
Thank you in advance.
(20min delay)